What are the funding trends in synthetic biology right now?

All funding deals in the synthetic biology market over the last years

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the Synthetic Biology Market.

Is synthetic biology funding actually booming right now?

Synthetic biology funding is having a very strong year in dollars, even though fewer financings are getting done.

We tracked $1.327 billion of known capital so far in 2026, up 79.5% from $740 million over the same period last year. Yet deal count slipped from 68 to 64, and the number of funded companies fell from 67 to 62.

The size of the rounds explains most of the gap. The median disclosed financing has climbed from $8.08 million to $13.52 million, while the average has risen from $15.41 million to $28.24 million.

The comparison with 2024 makes the picture clearer. Deal activity is only slightly higher today, with 64 financings versus 60, while known capital is 26.6% higher. Investors are currently putting much more money behind the companies they choose without funding many more companies.

Market measure	2026 YTD	2025 YTD	2024 YTD
Deals	64	68	60
Unique companies	62	67	60
Known capital	$1.327B	$740M	$1.048B
Median round	$13.52M	$8.08M	$13.00M
Average round	$28.24M	$15.41M	$22.79M
Largest round	$275M	$153M	$144M
First-financing share	23.4%	25.0%	21.7%
Follow-on share	75.0%	75.0%	78.3%

Are more synthetic biology startups getting funded, or are rounds just getting bigger?

Synthetic biology rounds are getting bigger; the population of funded startups is actually a little smaller than last year.

We counted 62 companies with a financing so far, down from 67 during the comparable 2025 period. The number of deals also fell by four.

Meanwhile, a typical disclosed round became roughly $5.4 million larger. The median now sits above $13.5 million, close to its 2024 level and far above the $8.1 million recorded last year.

That makes 2026 a fairly unusual funding year. A startup has not suddenly become much more likely to raise money simply because total funding has jumped. What has changed is how much capital can move once investors decide a company is worth backing.

Would synthetic biology funding still look strong without the megarounds?

Yes. Synthetic biology funding would still be clearly stronger than last year without the largest deals, although the headline growth would look much less spectacular.

Removing every financing above $50 million leaves about $630 million of known capital this year. The comparable 2025 figure was $468 million, so the market is still ahead by 34.8%.

The median round reinforces that conclusion because one or two enormous deals cannot push a median up very far. It rose 67.4% year over year.

The megarounds still carry a lot of weight. Encoded Therapeutics raised $275 million, BrainChild Bio raised $116 million and Tropic raised $105 million. Those three financings alone account for 37.4% of the capital we tracked.

The 2024 comparison is less flattering. After removing rounds above $100 million, current funding is about 8% below the comparable 2024 level. So 2026 looks genuinely stronger than 2025 across more than a handful of companies, while its apparent lead over 2024 depends much more heavily on the biggest checks.

Outlier test	2026 YTD	2025 YTD	2024 YTD
Known capital	$1.327B	$740M	$1.048B
Capital excluding >$50M	$630M	$468M	$563M
Capital excluding >$100M	$831M	$587M	$904M
Median round	$13.52M	$8.08M	$13.00M
Top 1 share of capital	20.7%	20.7%	13.7%
Top 3 share	37.4%	36.8%	28.5%
Top 5 share	48.4%	47.7%	40.5%
Rounds above $50M	6	3	6
Rounds above $100M	3	1	1

Why are synthetic biology funding rounds getting so much bigger?

Synthetic biology rounds are getting bigger because the center of gravity has moved away from small Seed deals and toward much better funded Series A rounds and milestone-heavy later financings.

Seed represented almost 40% of deals last year. Today it is below 30%. Series A has moved the other way, from 17.6% of financings to 32.8%.

You can see the same shift directly in deal sizes. Financings below $5 million have fallen from 26.5% of activity to 17.2%. Deals between $20 million and $50 million have almost doubled their share, and the $50 million to $100 million bracket is also much more common.

Companies getting funded are older too. Their median age has moved from three years to five years.

The market currently contains more companies that have had time to generate clinical data, build production capacity, validate a platform or reach the first stages of commercialization. Those companies need much larger rounds, and they now have a better case for getting them.

Are investors still funding brand-new synthetic biology startups?

Yes, brand-new synthetic biology companies are still getting funded, but they are barely participating in the big increase in capital.

We identified 15 first financings this year, compared with 17 last year and 13 in 2024. Their share of deal activity remains around one quarter, so there has been no collapse in the creation of new funded companies.

The money tells a different story. First financings account for about $102.5 million of known capital, while follow-on deals account for roughly $1.211 billion. The median first financing is $4 million; the median follow-on is $16 million.

That four-to-one difference gives a better sense of today's market than the overall funding total. Investors are still willing to try new companies, but most of the extra money is going into businesses that have already raised before.

Our first-financing classification comes from a public financing-history check rather than a perfect reconstruction of every private round ever completed, so we would not read too much into a one- or two-deal change. The gap in capital is large enough to be much harder to dismiss.

Is synthetic biology becoming a late-stage funding market?

Synthetic biology has not suddenly turned into a late-stage market; the much bigger change is the jump from Seed into Series A.

Later-stage deals represent 15.6% of current activity, almost identical to last year's 16.2%. What changed sharply was the early part of the funding ladder.

We found 19 Seed rounds and 21 Series A rounds this year. During the comparable 2025 period there were 27 Seed rounds and only 12 Series A financings.

Series A is also much better funded now. This is where a large part of the middle-market expansion is happening.

Large Series C and Series D+ rounds still swallow a disproportionate amount of capital, especially because of several exceptional therapeutic deals. They do not represent a broad migration of the entire sector toward growth-stage financing.

Is synthetic biology therapeutics taking over the funding market?

Synthetic biology therapeutics is currently taking more than half of all known funding while accounting for fewer than one in five deals.

We tracked 12 therapeutic financings worth about $683 million. That gives the category 18.8% of deals and 51.5% of the capital.

The jump in round size is huge. The category's median financing has reached $50 million, compared with $7.6 million last year. Deal count rose by only three, so the funding surge cannot be explained by a flood of new therapeutic companies.

Encoded Therapeutics is the biggest example with its $275 million financing. BrainChild Bio added a $116 million Series A, Epicrispr raised $90 million and Typewriter Therapeutics recently emerged with a $56 million Series A.

That group shows how different the upper end of therapeutic synthetic biology looks these days. A handful of companies are now financing clinical programs with checks closer to mainstream later-stage biotech than to the traditional image of an early synthetic biology startup.

Why are synthetic biology therapeutics raising so much money now?

The recent synthetic biology therapeutics boom lines up closely with companies reaching expensive and much more concrete clinical milestones.

Encoded Therapeutics is the clearest case. Before closing its $275 million financing, the company had moved ETX101 into pivotal development for Dravet syndrome. Encoded also reported updated Phase 1/2 results showing sustained seizure reductions and developmental gains, while the new capital will support the pivotal program and scale its internal GMP manufacturing.

Epicrispr's $90 million Series C followed first-in-human progress with EPI-321 in FSHD. The company had completed enrollment and dose escalation and had already reported early clinical activity before raising capital aimed at moving the program toward pivotal studies.

BrainChild Bio announced its $116 million Series A as BCB-276 moved into a pivotal Phase 2 trial for DIPG. BrainChild already had FDA Breakthrough Therapy and RMAT designations around the program.

These deals make the current concentration in therapeutics easier to understand. Investors are paying up when technical risk has been replaced by clinical execution risk and when the next phase of development requires tens or hundreds of millions of dollars.

Funding data alone cannot prove that clinical progress caused every round. Across several of the year's largest financings, though, the timing is unusually consistent.

Is synthetic biology food finally moving from the lab into the real market?

Some synthetic biology food companies are now raising around commercial scale-up rather than just proving the technology works.

Food generated 11 deals and about $220 million of known capital this year, up from nine deals and roughly $73 million over the same period in 2025. The median round has risen from $4.5 million to $18.3 million.

Tropic is the strongest example. The company raised $105 million after launching new banana varieties commercially, and it says demand for its non-browning and extended-shelf-life bananas is already above supply. The money is going into production scale-up, distribution and further banana and rice varieties.

Vivici gives us another useful angle. The precision-fermentation company has already commercialized beta-lactoglobulin and launched fermentation-derived lactoferrin in the US. Its latest European Innovation Council package supports additional supply and market expansion.

The category still contains companies at very different levels of maturity, and Tropic accounts for a large piece of this year's capital. Still, food funding currently has more commercial evidence behind it than it did during much of the earlier precision-fermentation cycle.

Are synthetic biology biofoundries making a comeback?

Biofoundry funding has come back strongly in dollars, although the number of deals has actually fallen.

The category produced 12 financings this year, down from 16, while known capital rose from roughly $59 million to $199 million. Its median round more than doubled to $12.1 million.

Adaptyv Biosystems is one of the freshest examples. The company raised a $40 million Series A after opening its automated wet lab to outside protein designers and launching an API that lets software and AI agents submit biological experiments directly.

The timing is interesting because the product itself has also become more ambitious. Adaptyv recently reported wet-lab tests of more than 1,300 protein designs generated through Anthropic's Claude workflows, while its automated infrastructure turns digital designs into physical experiments.

Avenue Biosciences raised a smaller $5.7 million extension to scale high-throughput protein engineering and manufacturing tools. Together, these companies show why biofoundries remain investable even without a higher deal count: the pitch is increasingly about infrastructure that can shorten real biological development cycles, especially as AI produces far more designs that need to be tested.

Which synthetic biology categories are actually gaining and losing investor attention?

Therapeutics, food and biofoundries are taking much larger checks today, while materials, engineered microbes and design software have had a much softer year in different ways.

Engineered microbes fell from 18 deals to 10 and from $200 million to $150 million of known capital. That looks sharp against 2025, although the category is still raising more capital than it did over the comparable 2024 period.

Materials went in a completely different direction. Deal count increased to 14, the highest of any category, while known capital fell to only $58 million. Investors are still funding plenty of materials companies; the checks are simply much smaller.

Design software is a tiny sample, but the current pattern is similarly weak in dollars. Five financings produced around $18 million, compared with three deals and $45 million last year.

The category rotation is more useful than a simple ranking. Therapeutics has both enormous capital intensity and major clinical milestones. Food is gaining both deals and dollars. Biofoundries are doing fewer but larger financings. Materials has plenty of activity without much financial weight.

Category	2026 deals	2026 known capital	2026 median	2025 known capital
Therapeutics	12	$683M	$50.0M	$238M
Food	11	$220M	$18.3M	$73M
Biofoundry	12	$199M	$12.1M	$59M
Engineered microbes	10	$150M	$14.1M	$200M
Materials	14	$58M	$9.8M	$125M
Design software	5	$18M	$9.0M	$45M
Total market	64	$1.327B	$13.52M	$740M

Is North America really dominating synthetic biology funding right now?

North America dominates synthetic biology dollars today, even though most of the deals we found happened somewhere else.

North American companies account for only 14 of the 64 financings, or 21.9% of the market by deal count. Those rounds captured 53.3% of known capital.

That imbalance comes largely from the therapeutic financing wave. Encoded, BrainChild Bio, Epicrispr and Typewriter all sit in that part of the market.

Europe looks much more balanced, with 21 deals and 30.4% of known funding.

Asia-Pacific is the tricky region. We found 27 deals there, making it the largest geography by activity, but only 11 have precise usable amounts. Many Chinese announcements disclose figures as broad descriptions such as tens of millions of renminbi.

So APAC is clearly very active. We do not have enough disclosed amounts to claim with the same confidence that it receives only a small fraction of the market's real capital.

Are corporate investors coming back to synthetic biology?

Corporate investors are showing up more often in synthetic biology deals again, especially where the technology is close to a product, manufacturing process or strategic market.

We found a strategic investor in 26.6% of 2026 financings, up from 19.1% last year. The current level is still slightly below the 28.3% we saw in 2024, so this looks more like a rebound than a completely new era.

Tropic is a good example of why these investors are appearing. Corteva co-led its $105 million round through Corteva Catalyst as Tropic scales gene-edited crops into commercial agriculture.

Epicrispr's financing included Sanofi Ventures and Angelini Ventures while EPI-321 moved closer to pivotal development. In materials and industrial biology, strategic participation also tends to come from companies with obvious downstream exposure to ingredients, chemicals, textiles or manufacturing.

Corporate money currently looks most convincing when the startup has reached a point where the investor can see a direct strategic use for what is being built. That is a much more practical relationship than the broad corporate experimentation we have sometimes seen in earlier synthetic biology cycles.

Is the synthetic biology investor base actually getting broader?

More lead investors are visible in synthetic biology this year, but better disclosure explains part of the increase.

We identified 73 unique leads in 2026, up from 56 over the comparable 2025 period. Only Daphni, Janus Henderson Investors, Alven and Shanghai State-Owned Capital Investment Pilot appear as leads on more than one deal, with two each.

That looks fairly diverse. The catch is that we know the lead investor for 82.8% of current deals versus only 67.6% last year. Naturally, we find more unique investors when more syndicates are publicly identified.

The useful takeaway is narrower. Synthetic biology funding today is coming from a wide mix of specialist biotech investors, generalist venture firms, growth funds, corporates and state-linked investors. We do not see a small group repeatedly leading most of the market.

The exact year-over-year increase in investor breadth should be treated cautiously because the underlying disclosure improved so much.

Are synthetic biology investors becoming more selective?

Synthetic biology investors look more selective about who gets a large check, and that selectivity is probably the defining feature of the market right now.

The average funded company is older than it was last year. Follow-on companies absorb the overwhelming majority of capital. Therapeutics takes more than half of known dollars with fewer than one fifth of the deals. Meanwhile, the five largest financings account for 48.4% of the market.

At the same time, smaller deals have not disappeared. We still found Seed financings, first-time fundraises and active categories such as materials where many companies are raising modest amounts.

The split appears further up the funding ladder. Once a company has strong clinical evidence, a commercial product, serious manufacturing infrastructure or enough platform validation to justify scaling, investors can now write a very large check.

That is why 2026 feels much stronger in the headlines than it probably feels to every founder trying to raise. Capital is available, but the really big money is clustering around companies that have already given investors something concrete to underwrite.

Has synthetic biology already raised more in 2026 than in all of 2025?

Synthetic biology has already raised slightly more known capital than it did during the whole of 2025, despite completing far fewer deals.

Full-year 2025 produced about $1.288 billion of known funding across 99 financings. Current 2026 funding has reached $1.327 billion from 64 deals.

That means the market has already reached roughly 103% of last year's capital with only about 65% of last year's number of transactions.

Against full-year 2024, current capital is already at roughly 97.5%, while deal count is at 82.1%.

We would not extend those numbers mechanically through the rest of the year. A market containing $275 million, $116 million and $105 million rounds is too lumpy for a simple monthly extrapolation to tell us much.

What the comparison does show is how capital-heavy 2026 has become. Roughly a full year's worth of money has moved through the market well before a full year's worth of deals has taken place.

What is actually changing in synthetic biology funding?

Synthetic biology funding is much stronger in dollars today, but the market has not broadened. Fewer companies have raised than last year, and the number of financings has also slipped. The extra money is coming from bigger rounds.

The rise is real beyond the headline deals. As seen above, removing financings above $50 million still leaves funding 34.8% ahead of last year's comparable period. That gives the current rebound considerably more substance than a single-megaround story.

The companies receiving the largest checks are further along. Seed has lost ground to Series A, follow-on financings dominate the dollars and the median age of a funded company has increased. Investors currently seem much happier paying up after technical, clinical or commercial de-risking than expanding the number of companies they back.

Therapeutics is the clearest winner. Clinical-stage companies now absorb more than half of known synthetic biology funding, and several of the largest rounds arrived alongside pivotal studies, human data or other tangible development milestones.

Food and biofoundries also look healthier than they did last year. Tropic is financing commercial crop scale-up, Vivici is expanding already launched precision-fermentation ingredients, and Adaptyv is building automated wet-lab infrastructure around a rapidly growing volume of AI-designed proteins.

Other parts of synthetic biology are having a much more ordinary year. Materials has plenty of deals but small checks, engineered microbes has cooled from a strong 2025, and design software remains a small market. Anyone talking about a broad synthetic biology funding boom is flattening several very different markets into one number.

The clearest description of 2026 is a selective reacceleration. Investors are putting much more capital into synthetic biology companies that have crossed meaningful technical, clinical or commercial milestones, while funding access across the wider startup population has changed far less.